Arkolith/Insider Trading/TAK/Form 4

Gillis Steven

DirectorTAKEDA PHARMACEUTICAL CO LTD (TAK) · full profile →Form 4 · filed Jul 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2026Grant(A)4K—$010K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2026Disposed to issuer(D)1K$4931.20$5.7M0
Jul 1, 2026Grant(A)1K—$01K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001395064-26-000276) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML